Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pompe disease is a rare autosomal recessive lysosomal storage disorder caused by mutations in the GAA gene, with an estimated incidence of 1 in 40,000 live…
Bayer is paying up to $4 billion to acquire AAV gene therapy company AskBio, the German pharma's biggest cell and gene therapy bet to date. The deal hands…
The U.S. Food and Drug Administration today approved Nexviazyme (avalglucosidase alfa-ngpt) for adults and children with late-onset Pompe disease. Nexviazyme…
Source summaries from our enrichment pipeline; follow links for originals.
All 15 sources with sentiment breakdown →
Bayer agreed to acquire Asklepios BioPharmaceutical (AskBio) for $2B upfront plus up to $2B in success-based milestones (~75% expected within five years). Brought industry-leading AAV gene therapy platform with proprietary Pro10 manufacturing and extensive AAV capsid/promoter library. Lead clinical programs in Pompe disease, Parkinson's, and congestive heart failure. AskBio operates independently post-close.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Asklepios BioPharmaceutical, Inc. (AskBio) (this deal) | 2020 | $4.0B | — |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2020 deals · Bayer AG deals · Cardiovascular deals